Prodrug - WordPress.com
... Soft drugs are active compounds that after exerting its action undergo inactivation to give a nontoxic product. Indeed soft drugs are a group of modified compounds that are also designed to delivery the drugs in to the brain (the chemical delivery system). Bodor coined the term. ...
... Soft drugs are active compounds that after exerting its action undergo inactivation to give a nontoxic product. Indeed soft drugs are a group of modified compounds that are also designed to delivery the drugs in to the brain (the chemical delivery system). Bodor coined the term. ...
Eleventh Specialty Pharma Newsletter (December 2009)
... Administration today expanded the approved use of Tamiflu (oseltamivir) to treat children as young as 2 weeks old who have shown symptoms of flu for no longer than two days. The drug is not approved to prevent flu infection in this population. In addition, the safety and efficacy of Tamiflu to treat ...
... Administration today expanded the approved use of Tamiflu (oseltamivir) to treat children as young as 2 weeks old who have shown symptoms of flu for no longer than two days. The drug is not approved to prevent flu infection in this population. In addition, the safety and efficacy of Tamiflu to treat ...
Acucela: Pursuit of Science through Innovation
... • Main business: Development efforts based on our proprietary Visual Cycle Modulation, or VCM, compounds – Emixustat hydrochloride: Acucela’s proprietary investigational compound based on VCM technology – Orally administered investigational new drug product candidate for the potential treatment of g ...
... • Main business: Development efforts based on our proprietary Visual Cycle Modulation, or VCM, compounds – Emixustat hydrochloride: Acucela’s proprietary investigational compound based on VCM technology – Orally administered investigational new drug product candidate for the potential treatment of g ...
Factors affecting drug metabolism
... with glucuronic acid appears to be responsible for the accumulation of toxic levels of this drug….. This will lead to what is called gray-baby syndrome. Neonatal hyperbilirubinemia results from the ...
... with glucuronic acid appears to be responsible for the accumulation of toxic levels of this drug….. This will lead to what is called gray-baby syndrome. Neonatal hyperbilirubinemia results from the ...
PDF
... Which of the following statements is true? A. Drugs must physically interact with each other to cause a drug-drug interaction B. If food slows down the rate of absorption of a drug, but not the extent, it is not considered a drug interaction C. If a drug can worsen a patient’s comorbid medical condi ...
... Which of the following statements is true? A. Drugs must physically interact with each other to cause a drug-drug interaction B. If food slows down the rate of absorption of a drug, but not the extent, it is not considered a drug interaction C. If a drug can worsen a patient’s comorbid medical condi ...
Antimicrobial Medications
... Drugs is extracted from broth medium Antibiotic extensively purified In some cases drugs are chemically altered to impart new characteristics Termed semi-synthetic ...
... Drugs is extracted from broth medium Antibiotic extensively purified In some cases drugs are chemically altered to impart new characteristics Termed semi-synthetic ...
- BioTek Instruments
... Introduction High throughput screening (HTS), or the process by which libraries of small molecule compounds are individually assessed for binding, activating or inactivating biological activity in drug target molecules, has been part of the drug discovery process for more than two decades. Its prima ...
... Introduction High throughput screening (HTS), or the process by which libraries of small molecule compounds are individually assessed for binding, activating or inactivating biological activity in drug target molecules, has been part of the drug discovery process for more than two decades. Its prima ...
ANTI FUNGAL DRUGS
... Febrile reactions can be mitigated by hydrocortisone 25-50 mg before each infusion. ...
... Febrile reactions can be mitigated by hydrocortisone 25-50 mg before each infusion. ...
`Spice` and other herbal blends: harmless incense or cannabinoid
... their metabolites do not show significant cross-reactivity to the used assay. This is so far the first time cannabinoid-like designer drugs were used as adulterants in commercially available products designed for inhalative application. Compounds 2 and 3 are strong cannabinoid receptor agonists and ...
... their metabolites do not show significant cross-reactivity to the used assay. This is so far the first time cannabinoid-like designer drugs were used as adulterants in commercially available products designed for inhalative application. Compounds 2 and 3 are strong cannabinoid receptor agonists and ...
vocsigjan98
... • Routes are fully defined by a site of administration and a method of administration • Site and method are related and form an association -- route is a composite entity • Dose Form is related to route through the site of administration since they constrain each other • Similar (but not quite) to H ...
... • Routes are fully defined by a site of administration and a method of administration • Site and method are related and form an association -- route is a composite entity • Dose Form is related to route through the site of administration since they constrain each other • Similar (but not quite) to H ...
sulfonamides-part-1
... The d-Ala d-Ala sequence is targeted by transpeptidase for cross-link formation. D-Ala isn’t present in vertebrates. The terminal d-Ala is cleaved, and the remaining one forms a covalent complex with the enzyme. This covalent bond to the dAla is then replaced with the peptide bond cross-link to an ...
... The d-Ala d-Ala sequence is targeted by transpeptidase for cross-link formation. D-Ala isn’t present in vertebrates. The terminal d-Ala is cleaved, and the remaining one forms a covalent complex with the enzyme. This covalent bond to the dAla is then replaced with the peptide bond cross-link to an ...
legal aspects of medication administration
... Explain differences between the chemical, generic, official, and brand names of medicines List the basic types of drug actions Describe the four basic physiologic processes that affect medications in the body Copyright © 2013, 2010, 2006, 2003, 2000, 1995, 1991 by Mosby, an imprint of Elsevier ...
... Explain differences between the chemical, generic, official, and brand names of medicines List the basic types of drug actions Describe the four basic physiologic processes that affect medications in the body Copyright © 2013, 2010, 2006, 2003, 2000, 1995, 1991 by Mosby, an imprint of Elsevier ...
11_Bioequivalence
... another product if it contains the same active substance or therapeutic moiety and, clinically, shows the same efficacy and safety as that product, whose efficacy and safety has been established. • In practice, demonstration of bioequivalence is generally the most appropriate method of substantiatin ...
... another product if it contains the same active substance or therapeutic moiety and, clinically, shows the same efficacy and safety as that product, whose efficacy and safety has been established. • In practice, demonstration of bioequivalence is generally the most appropriate method of substantiatin ...
Cocaine, Stimulants, and MDMA
... thousands of years to increase energy. Plant-derived stimulants have been refined and new drugs developed to increase potency and duration. As potency increases negative effects become apparent. ...
... thousands of years to increase energy. Plant-derived stimulants have been refined and new drugs developed to increase potency and duration. As potency increases negative effects become apparent. ...
Optimization of Healthcare Operations: the eHealth Added
... – Controlling the release of evidence-based order sets to ensure that current, approved versions are in use – Updating evidence-based order sets to reflect changes in local practice, performance measures, or the peer-reviewed literature – Preserving a library and archive of institution-wide evidence ...
... – Controlling the release of evidence-based order sets to ensure that current, approved versions are in use – Updating evidence-based order sets to reflect changes in local practice, performance measures, or the peer-reviewed literature – Preserving a library and archive of institution-wide evidence ...
Drug Interactions
... he will not discuss any off-label indications for drugs used for the treatment of HIV infection. He will discuss drug-drug interaction information that has been presented at scientific meetings or published, which is not included in the FDA approved package insert. ...
... he will not discuss any off-label indications for drugs used for the treatment of HIV infection. He will discuss drug-drug interaction information that has been presented at scientific meetings or published, which is not included in the FDA approved package insert. ...
Department of Pharmacology
... Student’s attendance during the seminars is mandatory – only 1 unjustified absence during the whole course will be accepted. The absence during the seminar must be justified by a duly authorised document (doctor’s note, University’s letter, letter from other authorities, etc.) Students with un ...
... Student’s attendance during the seminars is mandatory – only 1 unjustified absence during the whole course will be accepted. The absence during the seminar must be justified by a duly authorised document (doctor’s note, University’s letter, letter from other authorities, etc.) Students with un ...
Party DRUGS - Australian Doctor
... for the first time’. • Coming down. The effects of the drug start to wear off (‘what goes up must come down’), as serotonin levels become depleted. During this stage the user feels tired and often physically exhausted (especially if dancing through the night) with muscle aches and pains, and difficu ...
... for the first time’. • Coming down. The effects of the drug start to wear off (‘what goes up must come down’), as serotonin levels become depleted. During this stage the user feels tired and often physically exhausted (especially if dancing through the night) with muscle aches and pains, and difficu ...
Dea free
... Enforcement Administration (DEA) is a United States federal law enforcement agency under the U.S. Department of Justice, tasked with combating drug smuggling. The US Drug Enforcement Agency (DEA) have given their permission for clinical trials to begin for therapeutic use of marijuana on veterans su ...
... Enforcement Administration (DEA) is a United States federal law enforcement agency under the U.S. Department of Justice, tasked with combating drug smuggling. The US Drug Enforcement Agency (DEA) have given their permission for clinical trials to begin for therapeutic use of marijuana on veterans su ...
Key Residues Controlling Binding of Diverse Ligands to Human
... (Protein Data Bank code 1Z11) (Yano et al., 2005). Mutations of CYP2A13 were performed in silico via the Biopolymer suite in Insight-II (Accelrys, San Diego, CA), and each unique mutant protein was allowed to relax via CHARMM simulations (Brooks et al., 1983), entailing a 100-step molecular mechanic ...
... (Protein Data Bank code 1Z11) (Yano et al., 2005). Mutations of CYP2A13 were performed in silico via the Biopolymer suite in Insight-II (Accelrys, San Diego, CA), and each unique mutant protein was allowed to relax via CHARMM simulations (Brooks et al., 1983), entailing a 100-step molecular mechanic ...
What Is Addiction?
... • Lysergic Acid Diethylamide (LSD) (acid) – In 1970 it was placed on controlled substances list. – About 6 percent of Americans between age 18 and 25 have used LSD at least once in their lifetime. – Commonly sold as a "blotter" on paper, it is one of the most powerful drugs known to science, and ...
... • Lysergic Acid Diethylamide (LSD) (acid) – In 1970 it was placed on controlled substances list. – About 6 percent of Americans between age 18 and 25 have used LSD at least once in their lifetime. – Commonly sold as a "blotter" on paper, it is one of the most powerful drugs known to science, and ...
THE CROSSROADS OF PHARMACEUTICAL
... between. One problem is that the evidence is destroyed by patient use. Another is that the effects of a counterfeit pharmaceutical are often attributed to an underlying disease. If a patient dies, the cause of death will typically be related to the underlying disease process, and not as a result of ...
... between. One problem is that the evidence is destroyed by patient use. Another is that the effects of a counterfeit pharmaceutical are often attributed to an underlying disease. If a patient dies, the cause of death will typically be related to the underlying disease process, and not as a result of ...
Drug design
Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.The phrase ""drug design"" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.